Business Context and Reporting Period
This Form 8-K is a current report filed by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) on June 17, 2005, regarding events that occurred on June 14, 2005. The company is incorporated in Delaware and is headquartered in Rockville, Maryland.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Board Resignations: Suk Hyung Kwon and Jang Han Rhee resigned from the Board of Directors effective immediately on June 14, 2005.
- Board Election: Tae Heum Jeong, the Company's Chief Financial Officer and Secretary, was elected as a Director to fill one of the vacancies created by the resignations.
Management Commentary and Employment Details
Mr. Jeong has served as CFO and Secretary since May 2005 and previously held the same role at the company's wholly owned subsidiary, Rexahn Corp, from December 2002 to May 2005. His employment agreement, dated December 1, 2002, sets his annual base salary at $100,000 (increased from $50,000 in August 2003). The agreement includes a non-compete clause and allows for termination without cause upon 14 days' written notice by either party, or immediate termination by the company under specific events such as asset sales, mergers, or bankruptcy. Upon termination, Mr. Jeong must exercise vested stock options within 30 days or they will expire. There are no established Board committees at this time.
Investor Verification Checklist
- Verify the reason for the simultaneous resignations of Suk Hyung Kwon and Jang Han Rhee.
- Confirm the total number of Board vacancies remaining after Mr. Jeong's election.
- Review the company's most recent financial statements to assess liquidity, as this 8-K contains no financial data.
- Check for any pending litigation or disputes related to the departing directors.